Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients

Tefferi, 2014, An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms., Leukemia, 28, 1407, 10.1038/leu.2014.35 Wadleigh, 2010, Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria., Int J Hematol, 91, 174, 10.1007/s12185-010-0529-5 Vainchenker, 2008, JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies., Semin Cell Dev Biol, 19, 385, 10.1016/j.semcdb.2008.07.002 Defour, 2013, Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation., Proc Natl Acad Sci USA, 110, 2540, 10.1073/pnas.1211560110 Ding, 2009, The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity., Blood, 114, 3325, 10.1182/blood-2008-04-149047 Ding, 2004, Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin., Blood, 103, 4198, 10.1182/blood-2003-10-3471 Beer, 2008, MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort., Blood, 112, 141, 10.1182/blood-2008-01-131664 Chaligné, 2008, New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition., Leukemia, 22, 1557, 10.1038/leu.2008.137 He, 2013, Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases., J Hematol Oncol, 6, 11, 10.1186/1756-8722-6-11 Kawamata, 2008, Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray., Exp Hematol, 36, 1471, 10.1016/j.exphem.2008.06.006 Lambert, 2012, A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia., Am J Hematol, 87, 532, 10.1002/ajh.23138 Williams, 2007, Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis., Exp Hematol, 35, 1641, 10.1016/j.exphem.2007.08.010 Koren-Michowitz, 2013, SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F., Br J Haematol, 161, 811, 10.1111/bjh.12327 Oh, 2010, Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms., Blood, 116, 988, 10.1182/blood-2010-02-270108 Klampfl, 2013, Somatic mutations of calreticulin in myeloproliferative neoplasms., N Engl J Med, 369, 2379, 10.1056/NEJMoa1311347 Nangalia, 2013, Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2., N Engl J Med, 369, 2391, 10.1056/NEJMoa1312542 Wang, 2012, Calreticulin signaling in health and disease., Int J Biochem Cell Biol, 44, 842, 10.1016/j.biocel.2012.02.009 Tefferi, 2014, Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis., Blood, 124, 2507, 10.1182/blood-2014-05-579136 Tefferi, 2014, CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons., Leukemia, 28, 1472, 10.1038/leu.2014.3 Cervantes, 2005, Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging., Semin Oncol, 32, 395, 10.1053/j.seminoncol.2005.04.011 Barosi, 1999, The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia., Br J Haematol, 104, 730, 10.1046/j.1365-2141.1999.01262.x James, 2005, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera., Nature, 434, 1144, 10.1038/nature03546 Chaligné, 2007, Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis., Blood, 110, 3735, 10.1182/blood-2007-05-089003 Cabagnols, 2015, Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution., Leukemia, 29, 249, 10.1038/leu.2014.270 Saliba, 2015, Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies., Nat Genet, 47, 1131, 10.1038/ng.3380 Damm, 2014, Acquired initiating mutations in early hematopoietic cells of CLL patients., Cancer Discov, 4, 1088, 10.1158/2159-8290.CD-14-0104 Plo, 2008, JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders., Blood, 112, 1402, 10.1182/blood-2008-01-134114 Kohlhuber, 1997, A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses., Mol Cell Biol, 17, 695, 10.1128/MCB.17.2.695 Saharinen, 2002, The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction., J Biol Chem, 277, 47954, 10.1074/jbc.M205156200 Sliva, 1994, Growth hormone specifically regulates serine protease inhibitor gene transcription via gamma-activated sequence-like DNA elements., J Biol Chem, 269, 26208, 10.1016/S0021-9258(18)47180-3 Marty, 2014, Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors., Blood, 123, 1372, 10.1182/blood-2013-05-504555 Xie, 2014, Age-related mutations associated with clonal hematopoietic expansion and malignancies., Nat Med, 20, 1472, 10.1038/nm.3733 McKerrell, 2015, Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis., Cell Reports, 10, 1239, 10.1016/j.celrep.2015.02.005 Genovese, 2014, Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence., N Engl J Med, 371, 2477, 10.1056/NEJMoa1409405 Jaiswal, 2014, Age-related clonal hematopoiesis associated with adverse outcomes., N Engl J Med, 371, 2488, 10.1056/NEJMoa1408617 Klco, 2014, Functional heterogeneity of genetically defined subclones in acute myeloid leukemia., Cancer Cell, 25, 379, 10.1016/j.ccr.2014.01.031 Moliterno, 2006, Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression., Blood, 108, 3913, 10.1182/blood-2006-03-008805 Milosevic Feenstra, Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms., Blood Pardanani, 2010, LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations., Leukemia, 24, 1713, 10.1038/leu.2010.163 Velazquez, 2002, Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice., J Exp Med, 195, 1599, 10.1084/jem.20011883 Vilaine Moliterno, 2004, Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis., Proc Natl Acad Sci USA, 101, 11444, 10.1073/pnas.0404241101 Lannutti, 2009, Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis., Blood, 113, 1778, 10.1182/blood-2007-11-124859 Meyer, 2014, Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis., Blood, 124, 2280, 10.1182/blood-2014-03-560441 Ng, 2014, Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation., Proc Natl Acad Sci USA, 111, 5884, 10.1073/pnas.1404354111 Pecquet, 2010, Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor., Blood, 115, 1037, 10.1182/blood-2008-10-183558 Drachman, 1997, Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain., Proc Natl Acad Sci USA, 94, 2350, 10.1073/pnas.94.6.2350 Sangkhae, 2014, Phosphorylated c-Mpl tyrosine 591 regulates thrombopoietin-induced signaling., Exp Hematol, 42, 477, 10.1016/j.exphem.2014.02.007 Karow, Mutational profile of childhood myeloproliferative neoplasms [published online ahead of print July 30, 2015]., Leukemia